Vancomycin
FIRVANQ, TYZAVAN, Vancocin, Vancomycin
Glycopeptide Antibacterial
NADAC/unit
$0.3865
No Shortage
Tier 1: 127.7%
PA Req: 16.7%
21 Manufacturers
69 ANDAs
INDICATIONS AND USAGE Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-res....
vs. brand FIRVANQ: Generic saves up to 96% per unit
Active Shortages
2025-11-14 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
2025-09-09 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
2025-09-09 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
Market Intelligence
2024-04-24 Class I Recall: Amneal Pharmaceuticals of New York, LLC
2023-02-01 Class I Recall: Pfizer Inc.
Generic Manufacturers
ALKEM LABORATORIES LTDANI PHARMACEUTICALS INCASPIRO PHARMA LTDAZURITY PHARMACEUTICALS INCBAXTER HEALTHCARE CORPEUGIA PHARMA SPECIALITIES LTDEUROFARMA INCFRESENIUS KABI USA LLCGLAND PHARMA LTDHIKMA FARMACEUTICA PORTUGAL SAHIKMA PHARMACEUTICALSHIKMA PHARMACEUTICALS USA INCHOSPIRA INCLUPIN LTDMEITHEAL PHARMACEUTICALS INCMYLAN LABORATORIES LTDORIENT PHARMA CO LTDSAGENT PHARMACEUTICALS INCSAMSON MEDICAL TECHNOLOGIES LLCSLATE RUN PHARMACEUTICALS LLCSTERISCIENCE PTE LTDSTRIDES PHARMA GLOBAL PTE LTDXELLIA PHARMACEUTICALS APSZHEJIANG NOVUS PHARMACEUTICALS CO LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.